Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study
暂无分享,去创建一个
[1] M. Cooperberg,et al. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US , 2020, JAMA network open.
[2] A. D'Amico,et al. Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance. , 2020, JAMA.
[3] James D. Murphy,et al. African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance , 2020, Prostate Cancer and Prostatic Diseases.
[4] M. Cooperberg,et al. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. , 2020, European urology.
[5] Jonathan E. Shoag,et al. Active Surveillance for Black Men with Low-Risk Prostate Cancer in the United States. , 2019, The New England journal of medicine.
[6] D. Penson,et al. Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer , 2019, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] A. D'Amico,et al. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. , 2019, The New England journal of medicine.
[8] A. D'Amico,et al. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015 , 2019, JAMA.
[9] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options , 2018, The Journal of urology.
[10] J. Tward,et al. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database , 2018, Advances in radiation oncology.
[11] Ronald C. Chen,et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options , 2017, The Journal of urology.
[12] B. Hadaschik,et al. The Value of PSA Density in Combination with PI‐RADS™ for the Accuracy of Prostate Cancer Prediction , 2017, The Journal of urology.
[13] T. Choueiri,et al. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Menon,et al. Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013 , 2017, Clinical genitourinary cancer.
[15] E. Schaeffer,et al. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review , 2017, Prostate Cancer and Prostatic Diseases.
[16] David C. Miller,et al. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices , 2017, The Journal of urology.
[17] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[18] H. Lepor,et al. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. , 2016, The Journal of urology.
[19] M. Menon,et al. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. , 2016, European urology focus.
[20] M. Roobol,et al. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. , 2015, European urology.
[21] Simon P. Kim,et al. Contemporary Nationwide Patterns of Active Surveillance Use for Prostate Cancer. , 2015, JAMA internal medicine.
[22] M. Cooperberg,et al. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.
[23] M. Litwin,et al. Expectant management for men with early stage prostate cancer , 2015, CA: a cancer journal for clinicians.
[24] L. Holmberg,et al. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. , 2015, European urology.
[25] Sam S. Chang,et al. Increasing use of observation among men at low risk for prostate cancer mortality. , 2015, The Journal of urology.
[26] Danny Vesprini,et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] India U.S. Consulate Chennai. U.S. Department of Health & Human Services , 2014 .
[28] M. Roobol,et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.
[29] Alan W Partin,et al. Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .
[30] J. Mohler. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[31] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[32] A. D'Amico,et al. Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.
[33] J L Warren,et al. Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.
[34] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[35] S. Lipsitz,et al. Variation in the use of active surveillance for low‐risk prostate cancer , 2018, Cancer.
[36] Sanjay G. Patel,et al. National trends in the management of low and intermediate risk prostate cancer in the United States. , 2015, The Journal of urology.
[37] B. Trock,et al. Reclassification rates are higher among African American men than Caucasians on active surveillance. , 2015, Urology.
[38] David C. Miller,et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.
[39] Steven J. M. Jones,et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. , 2013, The Journal of urology.
[40] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.